Vaporox, a Denver based medical device startup, piqued investor interest at the recent “Angel Capital Summit 2019” sponsored by the Rockies Venture Club (RVC).  Vaporox then finished first in that conference’s “Venture Bucks” competition (see photo below), which bestows a coveted “People’s Choice” award for the best investment opportunity.

Vaporox’s technology, Vaperous Hyperoxia Therapy (“VHT”) is a breakthrough technology for healing skin wounds.  VHT employs ultrasonic waves to create an aqueous vapor containing an antimicrobial.  It then cycles between delivering this vapor and concentrated oxygen to the wound site during a treatment lasting one hour.  VHT penetrates into the recesses of the wound, and ultimately through the cell walls.  VHT is both much more effective and more comfortable for patients than existing treatments.  In a clinical study, VHT healed 87% of diabetic foot ulcers (DFUs) that had defied the current “gold standard” of wound care.

Learn more